Neovacs S.A. (PA:ALNEV) — Market Cap & Net Worth
Market Cap & Net Worth: Neovacs S.A. (ALNEV)
Neovacs S.A. (PA:ALNEV) has a market capitalization of $95.00 (€81.26) as of July 8, 2026. Listed on the PA stock exchange, this France-based company holds position #31783 globally and #600 in its home market, demonstrating a -12.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neovacs S.A.'s stock price €1.33 by its total outstanding shares 476625 (476.62K). See ALNEV capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Neovacs S.A. Market Cap History: 2023 to 2026
Neovacs S.A.'s market capitalization history from 2023 to 2026. Data shows growth from $278.61K to $741.11K (22.48% CAGR).
Neovacs S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neovacs S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.55x
Neovacs S.A.'s market cap is 1.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $278.61K | $533.41K | -$8.74 Million | 0.52x | N/A |
| 2024 | $569.04K | $366.35K | -$32.91 Million | 1.55x | N/A |
Competitor Companies of ALNEV by Market Capitalization
Companies near Neovacs S.A. in the global market cap rankings as of July 8, 2026.
Key companies related to Neovacs S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #430 globally with a market cap of $64.60 Billion USD.
- UCB SA (BR:UCB): Ranked #543 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #567 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $529.59 |
| #430 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $649.81 |
| #543 | UCB SA | BR:UCB | $49.68 Billion | €254.40 |
| #567 | Argen-X | BR:ARGX | $47.14 Billion | €813.00 |
Neovacs S.A. Historical Marketcap From 2023 to 2026
Between 2023 and today, Neovacs S.A.'s market cap moved from $278.61K to $ 741.11K, with a yearly change of 22.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €741.11K | +15187.36% |
| 2025 | €4.85K | -99.15% |
| 2024 | €569.04K | +104.24% |
| 2023 | €278.61K | -- |
End of Day Market Cap According to Different Sources
On Jul 7th, 2026 the market cap of Neovacs S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.00 USD |
| MoneyControl | $95.00 USD |
| MarketWatch | $95.00 USD |
| marketcap.company | $95.00 USD |
| Reuters | $95.00 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more